Experimental Alzheimer’s drug boosts SirT1 levels and improves memory in mice.

Researchers at the Drug Discovery Lab (DDL) at the Mary S. Easton Center for Alzheimer's Disease Research at UCLA have recently reported that an experimental drug known as A03, previously developed to treat depression, was found to increase brain levels of an enzyme Sirtuin1, or SirT1, and improve memory after oral treatment in mice genetically modified to have a protein called ApoE4, the most common genetic risk factor for AD. Increasing the levels of SirT1 may delay the buildup of the toxic tau pathology and improve cognition in Alzheimer's. The  DDL is conducting additional research on A03 to evaluate its potential for clinical testing in Alzheimer's disease. The lab is also developing similar compounds that might be more effective in increasing SirT1 levels.  The study was funded by the National Institute of Health.

UCLA Newsroom Research Alert - December 20, 2018:
"Experimental Alzheimer’s drug boosts SirT1 levels and improves memory in mice."